National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
Specialized Imaging Research Consortium™ (SIRC)
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Everolimus added to National Comprehensive Cancer Network (NCCN) Kidney Cancer Guidelines as subsequent therapy following failure of tyrosine kinase inhibitor therapy (TKI)

On Monday, April 13, 2009, everolimus was added to the NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer as a category 1 option for relapsed or unresectable stage IV disease in patients with predominant clear cell histology who have progressed on prior TKI therapy.